Management strategies for chronic liver disease-related thrombocytopenia
10.3760/cma.j.cn501113-20200609-00304
- VernacularTitle:慢性肝病相关血小板减少症管理策略
- Author:
Jiandan QIAN
1
;
Tiantian YAO
;
Yan WANG
;
Guiqiang WANG
Author Information
1. 北京大学第一医院感染疾病科暨肝病中心 100034
- Keywords:
Chronic liver disease;
Thrombocytopenia;
Thrombopoietin receptor agonists
- From:
Chinese Journal of Hepatology
2021;29(9):896-899
- CountryChina
- Language:Chinese
-
Abstract:
Chronic liver disease causes bleeding and coagulation system abnormalities through a variety of mechanisms. Thrombocytopenia is a common complication of chronic liver disease. Patients with chronic liver disease, especially liver cirrhosis, often face more invasive examinations or surgeries, which brings great challenges to clinical diagnosis and treatment. Traditional platelet transfusion is the main clinical intervention. With the approval of thrombopoietin receptor agonists, the current management standards for chronic liver disease-related thrombocytopenia may face changes. This article reviews the current main non-pharmacological and pharmacological interventions for chronic liver disease-related thrombocytopenia, and put forwards the corresponding clinical management improvement strategies based on the efficacy and limitations of these interventions.
